South Korea · Delayed Price · Currency is KRW GC Genome Statistics
Total Valuation
GC Genome has a market cap or net worth of KRW 120.15 billion. The enterprise value is 81.39 billion.
| Market Cap | 120.15B |
| Enterprise Value | 81.39B |
Important Dates
The last earnings date was Friday, April 10, 2026.
| Earnings Date | Apr 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GC Genome has 23.65 million shares outstanding. The number of shares has increased by 22.85% in one year.
| Current Share Class | 23.65M |
| Shares Outstanding | 23.65M |
| Shares Change (YoY) | +22.85% |
| Shares Change (QoQ) | +1.11% |
| Owned by Insiders (%) | 15.56% |
| Owned by Institutions (%) | 4.04% |
| Float | 13.04M |
Valuation Ratios
The trailing PE ratio is 25.56 and the forward PE ratio is 22.18.
| PE Ratio | 25.56 |
| Forward PE | 22.18 |
| PS Ratio | 3.74 |
| PB Ratio | 1.52 |
| P/TBV Ratio | 1.53 |
| P/FCF Ratio | 91.07 |
| P/OCF Ratio | 73.68 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.24, with an EV/FCF ratio of 61.69.
| EV / Earnings | 17.84 |
| EV / Sales | 2.53 |
| EV / EBITDA | 17.24 |
| EV / EBIT | 41.65 |
| EV / FCF | 61.69 |
Financial Position
The company has a current ratio of 9.80, with a Debt / Equity ratio of 0.05.
| Current Ratio | 9.80 |
| Quick Ratio | 9.18 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.94 |
| Debt / FCF | 2.95 |
| Interest Coverage | 7.38 |
Financial Efficiency
Return on equity (ROE) is 8.11% and return on invested capital (ROIC) is 3.10%.
| Return on Equity (ROE) | 8.11% |
| Return on Assets (ROA) | 1.34% |
| Return on Invested Capital (ROIC) | 3.10% |
| Return on Capital Employed (ROCE) | 1.70% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.49 |
| Inventory Turnover | 7.93 |
Taxes
In the past 12 months, GC Genome has paid 432.77 million in taxes.
| Income Tax | 432.77M |
| Effective Tax Rate | 8.67% |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 7,200.60 |
| 200-Day Moving Average | 7,420.55 |
| Relative Strength Index (RSI) | 26.30 |
| Average Volume (20 Days) | 190,051 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GC Genome had revenue of KRW 32.16 billion and earned 4.56 billion in profits. Earnings per share was 198.76.
| Revenue | 32.16B |
| Gross Profit | 14.99B |
| Operating Income | 1.40B |
| Pretax Income | 4.99B |
| Net Income | 4.56B |
| EBITDA | 4.17B |
| EBIT | 1.40B |
| Earnings Per Share (EPS) | 198.76 |
Balance Sheet
The company has 42.66 billion in cash and 3.90 billion in debt, with a net cash position of 38.76 billion or 1,638.82 per share.
| Cash & Cash Equivalents | 42.66B |
| Total Debt | 3.90B |
| Net Cash | 38.76B |
| Net Cash Per Share | 1,638.82 |
| Equity (Book Value) | 79.09B |
| Book Value Per Share | 3,304.62 |
| Working Capital | 48.58B |
Cash Flow
In the last 12 months, operating cash flow was 1.63 billion and capital expenditures -311.39 million, giving a free cash flow of 1.32 billion.
| Operating Cash Flow | 1.63B |
| Capital Expenditures | -311.39M |
| Depreciation & Amortization | 2.77B |
| Net Borrowing | -675.96M |
| Free Cash Flow | 1.32B |
| FCF Per Share | 55.78 |
Margins
Gross margin is 46.62%, with operating and profit margins of 4.36% and 14.18%.
| Gross Margin | 46.62% |
| Operating Margin | 4.36% |
| Pretax Margin | 15.53% |
| Profit Margin | 14.18% |
| EBITDA Margin | 12.96% |
| EBIT Margin | 4.36% |
| FCF Margin | 4.10% |
Dividends & Yields
GC Genome does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.85% |
| Shareholder Yield | -22.85% |
| Earnings Yield | 3.80% |
| FCF Yield | 1.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GC Genome has an Altman Z-Score of 13.71 and a Piotroski F-Score of 5.
| Altman Z-Score | 13.71 |
| Piotroski F-Score | 5 |